companies / synoxtherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 75,000,00075.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Dublin Ireland | |
| industry | unknown | |
| stage | series-b+ |
SynOx Therapeutics is developing emactuzumab, a monoclonal antibody against CSF-1R, to shut down macrophage-driven disease activity. It targets patients with tenosynovial giant cell tumor and other macrophage-driven rare diseases where treatment options are thin. Focusing all R&D on one antibody builds deeper macrophage-biology expertise than a broad pipeline allows.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | series-b | 75,000,00075.0M | null | ○ |
Cloudflare, reCAPTCHA, Slick 1.8.1, jQuery CDN, jQuery Migrate 3.4.1, PHP, cdnjs, Contact Form 7 6.1.6, Cookiebot, Vercel Speed Insights, Onsen UI, WordPress
| fact | status | src |
|---|---|---|
| Series B, $75.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |